Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116895 | 0.87 | RXFP1 (0.39) | NOTUMSTING1HPGDALDH1A1HTT | |
| SCHEMBL4128092 | 0.83 | ADAMTS5 (0.39) | ALDH1A1HTTKMT2A | |
| SCHEMBL4917700 | 0.83 | HTR6 (0.36) | STING1LMNAHTTMEN1KMT2A | |
| SCHEMBL4110694 | 0.82 | NOTUM (0.40) | NOTUMHPGDHIF1ALMNAHSD11B1 | |
| SCHEMBL4117459 | 0.82 | NOTUM (0.37) | NOTUMHPGDHIF1ALMNACTSA | |
| SCHEMBL4109519 | 0.81 | CYP11B2 (0.54) | HPGDLMNAKDM4EALDH1A1HTT | |
| SCHEMBL4127465 | 0.80 | MEN1 (0.42) | NOTUMHSD11B1ALDH1A1GRM2PLAU | |
| SCHEMBL4117131 | 0.75 | RXFP1 (0.38) | NOTUMHPGDALDH1A1HTTMEN1 | |
| SCHEMBL4115204 | 0.75 | ALDH1A1 (0.45) | HPGDLMNAKDM4EALDH1A1HTT | |
| SCHEMBL4117022 | 0.75 | FAAH (0.39) | HPGDHSD11B1KDM4EALDH1A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566378-B1 | ISOINDOLINE DERIVATIVE | MARUISHI PHARMA (JP) | 2012-08-15 | — | — | EP | disclosed |
| CN-100548980-C | The isoindoline derivative | MARUISHI PHARMA (JP) | 2009-10-14 | — | — | CN | disclosed |
| US-20090170835-A1 | ISOINDOLINE DERIVATIVES | MARUISHI PHARMACEUTICAL CO., LTD. | 2009-07-02 | — | — | US | disclosed |
| US-7521451-B2 | Isoindoline derivative | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20080021042-A1 | Composition For Controlling Neuropathic Pain | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
| CN-1956955-A | Neuropathic pain controlling agent composition | MARUISHI PHARMA (JP) | 2007-05-02 | — | — | CN | disclosed |
| EP-1749817-A1 | NEUROGENIC PAIN CONTROL AGENT COMPOSITION | Maruishi Pharmaceutical Co., Ltd. (JP) | 2007-02-07 | — | — | EP | disclosed |
| US-20060052392-A1 | e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction | MARUISHI PHARMACEUTICAL CO., LTD | 2006-03-09 | — | — | US | disclosed |
| CN-1741995-A | Isoindoline derivative | MARUISHI PHARMA (JP) | 2006-03-01 | — | — | CN | disclosed |
| EP-1566378-A1 | ISOINDOLINE DERIVATIVE | Maruishi Pharmaceutical Co., Ltd. (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052392-A1 | e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction | CYP3A5, OPRD1, CYP3A7 | NOTUM 1379/4885STING1 3478/4885HPGD 530/4885 |
| US-20080021042-A1 | Composition For Controlling Neuropathic Pain | GAP43, SCN10A, SCN2A | NOTUM 3785/4885STING1 1931/4885HPGD 2071/4885 |
| US-20090170835-A1 | ISOINDOLINE DERIVATIVES | OPRD1, OPRK1, OPRL1 | NOTUM 3062/4885STING1 1586/4885HPGD 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.